Genetics-guided supportive care study
This trial explores how genetic information can improve supportive care for people with incurable, life-limiting conditions. It aims to tailor treatments to reduce symptoms based on your DNA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a condition that cannot be cured and limits how long you live
- You receive your medical care at Norfolk and Norwich University Hospital (NNUH)
- You are able to consent to research, or have an appropriate person (consultee) who can give permission for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial aims to make genetic medicine better for people from ethnic minority groups. It will ask adults about their views to help improve healthcare for everyone.
This study tests whether a special program led by oncology nurses can help more people with solid tumor cancers get genetic testing. If you are starting a new treatment and have not had genetic testing before, this program may help you learn about your cancer risks and treatment options.
This trial studies how doing genetic (DNA) testing on your cancer helps doctors choose targeted treatments, and how those treatments affect outcomes. It is for adults whose cancer has not responded to the first standard treatment or who do not have curative options.
This trial is testing whether a new system that connects genetic test results to your medical records can help reduce healthcare gaps for people with advanced cancer. It may help your doctor better personalize your treatment.
This trial uses genetic information to help predict your risk of developing chronic diseases. It aims to create a platform that can identify health risks earlier so you can take preventive steps.
This study looks at using a genetic test (next-generation sequencing) to find cancer gene changes in stage IV hepatobiliary cancer. If there is a matching approved medicine, the study follows how well the “right drug for the right mutation” helps patients receiving palliative care.
Hear when a new Palliative Care trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.